Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: An ALWP EBMT study Journal Article


Authors: Fein, J. A.; Shouval, R.; Galimard, J. E.; Labopin, M.; Socié, G.; Finke, J.; Cornelissen, J. J.; Malladi, R.; Itälä-Remes, M.; Chevallier, P.; Orchard, K. H.; Bunjes, D.; Aljurf, M.; Rubio, M. T.; Versluis, J.; Mohty, M.; Nagler, A.
Article Title: Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: An ALWP EBMT study
Abstract: Older age and a high burden of comorbidities often drive the selection of low-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation recipients. However, the impact of comorbidities in the low-intensity conditioning setting is unclear. We sought to determine the contribution of individual comorbidities and their cumulative burden on the risk of nonrelapse mortality (NRM) among patients receiving low-intensity regimens. In a retrospective analysis of adults (≥18 years) who underwent transplantation for acute myeloid leukemia in the first complete remission between 2008 and 2018, we studied recipients of low-intensity regimens as defined by the transplantation conditioning intensity (TCI) scale. Multivariable Cox models were constructed to study associations of comorbidities with NRM. Comorbidities identified as putative risk factors in the low-TCI setting were included in combined multivariable regression models assessed for overall survival, NRM, and relapse. A total of 1663 patients with a median age of 61 years received low-TCI regimens. Cardiac comorbidity (including arrhythmia/valvular disease) and psychiatric disease were associated with increased NRM risk (hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.13-2.09 and HR, 1.69; 95% CI, 1.02-2.82, respectively). Moderate pulmonary dysfunction, though prevalent, was not associated with increased NRM. In a combined model, cardiac, psychiatric, renal, and inflammatory bowel diseases were independently associated with adverse transplantation outcomes. These findings may inform patient and regimen selection and reinforce the need for further investigation of cardioprotective transplantation approaches. © 2023 by The American Society of Hematology.
Keywords: adult; cancer survival; aged; major clinical study; overall survival; busulfan; fludarabine; cancer risk; outcome assessment; disease association; kidney disease; prevalence; relapse; retrospective study; risk assessment; adverse outcome; comorbidity; transplantation conditioning; mental disease; allogeneic hematopoietic stem cell transplantation; heart arrhythmia; graft recipient; valvular heart disease; acute myeloid leukemia; inflammatory bowel disease; cardiovascular mortality; disease burden; human; male; female; article; mortality risk
Journal Title: Blood Advances
Volume: 7
Issue: 10
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2023-05-23
Start Page: 2143
End Page: 2152
Language: English
DOI: 10.1182/bloodadvances.2022008656
PUBMED: 36622338
PROVIDER: scopus
PMCID: PMC10206431
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Roni Shouval
    149 Shouval